최소 단어 이상 선택하여야 합니다.
최대 10 단어까지만 선택 가능합니다.
다음과 같은 기능을 한번의 로그인으로 사용 할 수 있습니다.
NTIS 바로가기한국임상약학회지 = Korean journal of clinical pharmacy, v.34 no.1, 2024년, pp.1 - 20
한승훈 (우석대학교 약학대학) , 박태은 (우석대학교 약학대학)
This review examines the pivotal clinical trials that evaluated the efficacy and safety of semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, in the management of obesity. The reported findings underscore significant and sustained weight loss achieved with semaglutide in diverse patien...
Korean Society for the Study of Obesity. Clinical practice guidelines?for obesity, 8th edition. 2022:1-17.
Korean Society for the Study of Obesity. 2021 obesity fact sheet.?Available from https://www.kosso.or.kr/file/2021_Obesity_Fact_Sheet_web_kor.pdf?v2307210355. Accessed July 21, 2023.
Korean Diabetes Association. Clinical practice guidelines for diabetes. 2023:21-183.
Drucker DJ, Nauck MA. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type?2 diabetes. Lancet. 2006;368(9548):1696-705.
Holst JJ. Glucagonlike peptide 1: a newly discovered gastrointestinal?hormone. Gastroenterology 1994;107(6):1848-55.
Vilsboll T, Krarup T, Deacon CF, Madsbad S, Holst JJ. Reduced postprandial concentrations of intact biologically active glucagon-like?peptide 1 in type 2 diabetic patients. Diabetes 2001;50(3):609-13.
Clarke T. FDA approves Novo Nordisk diabetes drug Ozempic. Reuters. 2017. Available from https://www.reuters.com/article/idUSKBN1DZ2O8/. Accessed December 18, 2023.
U.S. Food and Drug Administration. FDA approves new drug treatment for chronic weight management, first since 2014. 2021. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-new-drug-treatment-chronic-weight-managementfirst-2014. Accessed December 18, 2023.
Ministry of Food and Drug Safety. Ozempic prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202201737aupdateTs2023-07-03%2017:55:00.0b. Accessed December 18, 2023.
Ministry of Food and Drug Safety. Wegovy prefilled pen (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202301387aupdateTs2023-12-15%2013:45:40.397763b. Accessed December 18, 2023.
U.S. Food and Drug Administration. FDA approves first oral GLP-1?treatment for type 2 diabetes. 2019. Available from https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-glp-1-treatment-type-2-diabetes. Accessed December 18, 2023.
Ministry of Food and Drug Safety. Rybelsus (semaglutide). Available from https://nedrug.mfds.go.kr/pbp/CCBBB01/getItemDetailCache?cacheSeq202201785aupdateTs2023-11-09%2011:24:14.969223b. Accessed December 18, 2023.
Sorli C, Harashima SI, Tsoukas GM, et al. Efficacy and safety of?once-weekly semaglutide monotherapy versus placebo in patients?with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a?trial. Lancet Diabetes Endocrinol 2017;5(4):251-60.
Rodbard HW, Lingvay I, Reed J, et al. Semaglutide Added to Basal Insulin in Type 2 Diabetes (SUSTAIN 5): A Randomized, Controlled?Trial. J Clin Endocrinol Metab 2018;103(6):2291-301.
Zinman B, Bhosekar V, Busch R, et al. Semaglutide once weekly as?add-on to SGLT-2 inhibitor therapy in type 2 diabetes (SUSTAIN 9):?a randomised, placebo-controlled trial. Lancet Diabetes Endocrinol?2019;7(5):356-67.
Ahmann AJ, Capehorn M, Charpentier G, et al. Efficacy and safety?of once-weekly semaglutide versus exenatide ER in subjects with?type 2 diabetes (SUSTAIN 3): A 56-week, open-label, randomized?clinical trial. Diabetes Care 2018;41(2):258-66.
Pratley RE, Aroda VR, Lingvay I, et al. Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a?randomised, open-label, phase 3b trial. Lancet Diabetes Endocrinol?2018;6(4):275-86.
Capehorn MS, Catarig AM, Furberg JK, et al. Efficacy and safety of?once-weekly semaglutide 1.0mg vs once-daily liraglutide 1.2mg as?add-on to 1-3 oral antidiabetic drugs in subjects with type 2 diabetes?(SUSTAIN 10). Diabetes Metab 2020;46(2):100-9.
Lingvay I, Catarig AM, Frias JP, et al. Efficacy and safety of?once-weekly semaglutide versus daily canagliflozin as add-on to?metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial. Lancet Diabetes?Endocrinol 2019;7(11):834-44.
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly?semaglutide in adults with overweight or obesity. N Engl J Med?2021;384(11):989-1002.
Rubino D, Abrahamsson N, Davies M, et al. Effect of continued?weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity: The STEP 4 randomized?clinical trial. JAMA 2021;325(14):1414-25.
Wadden TA, Bailey TS, Billings LK, et al. Effect of subcutaneous?semaglutide vs placebo as an adjunct to intensive behavioral therapy?on body weight in adults with overweight or obesity: The STEP 3?randomized clinical trial. JAMA 2021;325(14):1403-13.
Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of?semaglutide in adults with overweight or obesity: the STEP 5 trial.?Nat Med 2022;28(10):2083-91.
Weghuber D, Barrett T, Barrientos-Perez M, et al. Once-weekly semaglutide in adolescents with obesity. N Engl J Med?2022;387(24):2245-57.
Rubino DM, Greenway FL, Khalid U, et al. Effect of weekly subcutaneous semaglutide vs daily liraglutide on body weight in adults?with overweight or obesity without diabetes: The STEP 8 randomized clinical trial. JAMA 2022;327(2):138-50.
Frias JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. N Engl J Med?2021;385(6):503-15.
McGowan BM, Houshmand-Oeregaard A, Laursen PN, Zeuthen?N, Baker-Knight J. Impact of BMI and comorbidities on efficacy of?once-weekly semaglutide: Post hoc analyses of the STEP 1 randomized trial. Obesity (Silver Spring) 2023;31(4):990-28.
Wilding JPH, Batterham RL, Davies M, et al. Weight regain and?cardiometabolic effects after withdrawal of semaglutide: The STEP 1?trial extension. Diabetes Obes Metab 2022;24(8):1553-64.
Aroda VR, Rosenstock J, Terauchi Y, et al. PIONEER 1: Randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes.?Diabetes Care 2019;42(9):1724-32.
Mosenzon O, Blicher TM, Rosenlund S, et al. Efficacy and safety of?oral semaglutide in patients with type 2 diabetes and moderate renal?impairment (PIONEER 5): a placebo-controlled, randomised, phase?3a trial. Lancet Diabetes Endocrinol 2019;7(7):515-27.
Pratley R, Amod A, Hoff ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 2019;394(10192):39-50.
Rodbard HW, Rosenstock J, Canani LH, et al. Oral semaglutide?versus empagliflozin in patients with type 2 diabetes uncontrolled on?metformin: The PIONEER 2 trial. Diabetes Care 2019;42(12):2272-81.
Yabe D, Nakamura J, Kaneto H, et al. Safety and efficacy of oral?semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled,?phase 3a trial. Lancet Diabetes Endocrinol 2020;8(5):392-406.
Yamada Y, Katagiri H, Hamamoto Y, et al. Dose-response, efficacy,?and safety of oral semaglutide monotherapy in Japanese patients with?type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised,?controlled trial. Lancet Diabetes Endocrinol 2020;8(5):377-91.
Zinman B, Aroda VR, Buse JB, et al. Efficacy, safety, and tolerability?of oral semaglutide versus placebo added to insulin with or without?metformin in patients with type 2 diabetes: The PIONEER 8 trial.?Diabetes Care 2019;42(12):2262-71.
Knop FK, Aroda VR, do Vale RD, et al. Oral semaglutide 50 mg?taken once per day in adults with overweight or obesity (OASIS 1):?a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet?2023;402(10403):705-19.
American Diabetes Association. Standards of care in diabetes - 2023. Diabetes Care 2023;46(Suppl. 1).
Blonde L, Umpierrez GE, Reddy SS, et al. American Association of?Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract?2022;28(10):923-1049.
Korean Diabetes Association. Clinical practice guidelines for diabetes, 7th edition. 2021:89.
Korean Diabetes Association. Clinical practice guidelines for diabetes, 8th edition. 2023:125.
Grunvald E, Shah R, Hernaez R, et al. AGA clinical practice guideline on pharmacological interventions for adults with obesity. Gastroenterology 2022;163(5):1198-225.
DrFirst. Ozempic this, Wegovy that: no matter what you call it,?semaglutide is having a moment. 2023. Available from https://drfirst.com/press-releases/ozempic-this-wegovy-that-no-matter-what-youcall-it-semaglutide-is-having-a-moment/. Accessed February 13, 2024.
McPhillips D. CNN exclusive: prescriptions for popular diabetes?and weight-loss drugs soared, but access is limited for some patients.?CNN. 2023. Available from https://edition.cnn.com/2023/09/27/health/semaglutide-equitable-access/index.html. Accessed February?13, 2024.
American Society of Health-System Pharmacists. Semaglutide injection. 2024. Available from https://www.ashp.org/drug-shortages/current-shortages/drug-shortage-detail.aspx?id813&loginreturnUrlSSOCheckOnly. Accessed February 13, 2024.
Klein HE. An ongoing crisis: semaglutide shortage raises dual concerns for obesity and diabetes treatment. American Journal of Managed Care. 2023. Available from https://www.ajmc.com/view/an-ongoing-crisis-semaglutide-shortage-raises-dual-concerns-for-obesity-and-diabetes-treatment. Accessed February 13, 2024.
Leitner DR, Fruhbeck G, Yumuk V, et al. Obesity and type 2 diabetes: two diseases with a need for combined treatment strategies -?EASO can lead the way. Obes Facts 2017;10(5):483-92.
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide?and cardiovascular outcomes in obesity without diabetes. N Engl J?Med 2023;389(24):2221-32.
Wegovy (semaglutide) [Package Insert] Novo Nordis; Bagsvaerd,?Denmark: 2022.
Park ET. Finally, a survey?...Is misuse of 'obesity treatment' okay??Medipana. 2023. Available from: https://www.medipana.com/article/view.php?news_idx317626. Accessed February 29, 2024.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.